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INTRODUCTION
Psychotic disorders are among the most disabling mental illnesses and represent one of the top 20% causes of socio-economic burden worldwide (1) . Psychiatric research has therefore substantially invested into better early detection strategies for these disorders (2) . The Clinical High Risk(CHR) concept (3) describes a mental state characterized by subthreshold psychotic symptoms, which differ quantitatively in their intensity from those of a full-blown psychosis(Supplementary material and Table 1 ). The CHR paradigm has become a well-established clinical avenue to early detect and potentially treat the psychosis high-risk states. Based on the CHR paradigm, researchers investigated the nature of the pre-psychotic phase, both from pathophysiological and epidemiological perspectives (4, 5) . These efforts have been challenged by a constantly declining incidence rate of psychosis among CHR patients (4, 6) , with roughly one third of not transitioned-CHR cases still experiencing sub-threshold symptoms, psychosocial impairments (7) and lower level of quality of life (8) . Thus, the CHR designation delineates a mental condition, which is burdensome per se and, in addition, is associated with a known set of comorbidities(e.g., depression, substance abuse, anxiety disorders) (9) . Therefore, predictive psychiatry has gradually broaden its scope from detecting disease transition, to encompassing adverse outcomes more broadly, e.g., functional deficits (10), treatment response (11) , persisting negative symptoms (12) or psychiatric comorbidities (13) .
Considering that clinical instruments alone detect only about 47% of transitions after three years (14) , efforts have been made to identify potential risk factors for psychosis in several symptomatological and biological readouts, or biomarkers, of the disorder (15) , so that individualized prognostication may be enhanced. The presence of environmental adverse events (16) , cognitive impairments (17) , neuromorphological (18) , electrophysiological (19) , and hematological (20) alterations, as well as resting-state (21) and task-related neural activity and connectivity anomalies (22) has been consistently reported in people at risk for psychosis, compared with healthy individuals. Some of these phenotypes have been associated with both disease course, and transition to the overt disease (4) . Therefore, the identification of reliable markers able to distinguish between atrisk and healthy populations may be potentially useful in clinical practice to monitor disease development and treatment outcome (23), and to obviate time-consuming CHRassessments. The two prevailing statistical approaches to address the challenge of singlesubject prediction are machine learning(ML) methods(e.g., support vector machine, LASSO regression, random forest), which can handle large databases and different data domains (24, 25) and Cox proportional hazard regression, a form of multivariate survival analysis (26) able to investigate time-to conversion trajectories. Recent research applying these methods has produced prognostic models able to stratify CHR patients into different risk classes according to their pre-test risk enrichment (27) or a set of combined predictors (28, 29) , or to predict patients' functional outcomes based on different data modalities with performance accuracies of up to 83% (10, 30) . Despite the great potential of these models, their applicability is still hindered by the methodological heterogeneity in the field. Indeed, CHR patients are identified by several clinical instruments and are characterized by subtypes with different level of risk (14) . Moreover, models' generalizability has been assessed through discrepant validation strategies across studies, ranging from the less replicable(i.e., single-site cross-validation), to the most robust (validation to external samples)(25). Thus, methodological approaches still lack standardized validation strategies testing clinical applicability under real-world conditions. One way to tackle these issues is to use a meta-analytic approach to quantitatively investigate models' performance across different outcomes, algorithms and data modalities. Although important contributions to this goal have been made (5, 29, 31) , to the best of our knowledge, the field is still lacking such an analysis. Investigating the field's heterogeneity would allow a comprehensive assessment of accuracy and validity of the existing diagnostic and prognostic models, an important prerequisite for establishing reliable tools for psychosis risk quantification in clinical care.
Our aim was to review the literature on ML-and Cox regression-based diagnostic, i.e., discriminating CHR from healthy individuals, and prognostic models, i.e., predictive approaches for transition or negative outcomes. Further, we performed a meta-analysis of models' performance, with the aim of investigating the effects of (I) data modality, (II) type of algorithm, and (III) validation paradigms. We expect that our results will elucidate the complexity of methods and data domains currently used in the predictive analytics arm of CHR research. This will facilitate a deeper understanding of the state-of-the-art within the field and may clarify the bottlenecks impeding clinical translation.
METHODS AND MATERIALS

Literature search
We conducted a systematic search of published original articles in English until June Figure S1 ).
A comprehensive list of all variables extracted by each study is reported in Supplementary
Material, section 2. Performance accuracy measures used for analyses comprised TP, FN, TN, FP, sensitivity (SE, TP/(TP+FN)), and specificity (SP, TN/(TN+FP)).
Data analysis
The meta-analysis of diagnostic models was conducted following previous work (33) .
Extracted SE and SP were converted to a confusion matrix tabulated across studies.
Publication bias was assessed both with overall diagnostic odds ratio(DOR) and precision estimates arising from sample size differences(i.e., more precision with higher weight), and modeling normal distributions of each with a random effects approach. This bivariate method was used to produce summary estimates of SE, SP, and confidence intervals(CI) that were used in forest plots, in addition to the analysis of moderators using mixed modeling. Moderators were age, sex, data modality, algorithm, presence of CV, type of CHR, being a multisite study and year of publication. For prognostic studies we investigated also follow-up time and prognostic target. Moderator analyses were conducted if a minimum of 10 models-for-variable were available, in order to decrease the standard error and maximize power in case of high between-study variance (36) , and by controlling for sample size and CV scheme-the latter factor overlapping with algorithm used. Results were corrected for False Discovery Rate(FDR). Likelihood ratios and DOR were produced using a Markov-Chain-Monte-Carlo approach within the mada toolbox. All analyses were conducted with R v3.6.0.
RESULTS
The systematic literature search detected 881 articles, from which 44 were considered eligible after screening for exclusion criteria, for a total of 12 diagnostic and 32 prognostic models( Figure S1 ). The final sample included 3707 patients for prognostic studies(mean age 20.41 years,~58% males), of which 320(~9%) were CHR patients investigated for non-transition outcomes(mean age: 19.25 years, 56% males), and 1052 used for diagnostic classification(mean age: 23.42 years,~59% males), of which 480(45%) were HC. 26 studies used ML(among which all diagnostic studies) and 18 were conducted with Cox regression(Table 2, S1).
Meta-analytic results
CHR individuals could be classified against HC with an overall SE of 78%(95%-CI:63%-83%) and SP of 77%(95%-CI:68%-84%), while across all prognostic models SE reached 67%(95%-CI:63%-70%) and SP 78%(95%-CI:73%-82%). Prognostic studies showed a publication bias (R 2 =0.26, p<.001), whereas diagnostic studies didn't (R 2 =0.07, p>.05, Figure S2 ). Performances of both models' categories are illustrated in two summary Receiving Operating Characteristic curves (Figure 1 ,2) and forest plots (Figure 3,4 ). Within diagnostic models, moderator effects of type of CHR and algorithm, data modality, presence of CV, and being a multisite study were not investigated because less than 10 models-per-factor were available (36) . We found no effects of moderator variables in either application domain (all p>0.1, Table S2 ), even when splitting the sample based on CV(Supplementary Material).
Effect of algorithm choice
19 ML studies employed a support vector machine algorithm(i.e., 73% (10,30,37-53)), while the rest used Gaussian process (11) or convex hull classification(54), randomized trees(55), greedy algorithm(20), random forest(5) and LASSO regression (56, 57) . All ML models were computed with CV, whereas studies using Cox regression either applied bootstrapping(28,58-62), reported apparent results(i.e., the model is tested in the same sample it was derived from) (63)(64-68), or lacked a validation procedure. Among the cross-validated studies, 58% applied leave-one-out CV, 3 of which nested, 7 used k-fold CV, 3 thereof in its repeated nested form. Only one study applied a leave-site-out CV(10), i.e., a form of internal-external validation (69) . Within prognostic studies, we found a main effect of CV/algorithm on SE(p=0.009; χ 2
(2) =6.96, p=0.031), i.e., cross-validated ML models reached a higher SE(71%, 95%-CI:67%-74%) than Cox regression ones(61%, 95%-CI:54%-68%, Figure 4 ).
Effect of data modality
Diagnostic models included the use of functional (37, 39, 43, 47, 48) and structural (46, 50, 70) magnetic resonance imaging(MRI), diffusion tensor imaging (49) , and behavioral models based on neurocognitive functions (42, 43) .
Models for prediction of transition to psychosis involved blood-based(20,56,73), electrophysiological (57, 74, 75) and neuroanatomical data, either using white and/or grey matter volume (38, 44, 51) or gyrification measures (55) . Clinical models were trained on prodromal positive and negative symptoms, functioning, and family risk associated with functional decline; the neurocognitive modality was based on executive functions and verbal IQ (41) or speech features (54, 76) . Multimodal approaches included different combinations of clinical, neuropsychological and demographic variables as well as genetic risk(28,51,52,77,78). One model was built on P300 amplitude from event-related potentials and socio-personal adjustment (62) . Functional outcomes were predicted with neuroanatomical (63, 9, 19 ) and blood-based biomarkers (11) , and two studies combined clinical and MRI measures (10, 30) . There were no effects of data modality on SE(p =0.172) or false positive rate (FPR)(p =0.606, Table S2 ).
Effect of sample characteristics
Performance accuracies were not influenced by age and sex of individuals (all p >0.1, Table S2 ). CHR in 86% of the studies fulfilled the UHR criteria (80), while 6 models were based on the genetic risk syndromes 22q11.2DS (38, 48, 49) or FR (39, 52, 53 
DISCUSSION
We conducted a systematic review and meta-analysis on 44 studies reporting prognostic and diagnostic models for a total of, respectively, 3707 and 572 CHR individuals, with the aim to quantitatively assess their accuracy, validity and heterogeneity. Our results point to a good models' performance overall and to a higher sensitivity of ML models compared to
Cox regression in prognostic studies. This effect was fully collinear with that of CV, mainly due to the complete overlap of this factor with algorithm type. Notably, there were no significant effects of data modality, CHR or CV type, prognostic target, or any other potential confounding variable(e.g., age distribution, sex, year of publication or follow-up interval time) on accuracy performance in our data. Noteworthy, in prognostic studies, we observed a publication bias, i.e., the tendency for studies with smaller sample sizes to report higher, potentially inflated, prediction accuracies (82) . This might have impacted our results (82) , so that we can't draw robust conclusions from our metanalytical findings.
Methodological differences and pitfalls
Prognostic models employing ML outperformed those that used Cox regression by 10% sensitivity. This finding may have resulted from a complex interplay of cohort-related and methodological heterogeneity. Notably, there was a complete overlap between the statistical method chosen and implementation of CV, i.e., all ML models were cross validated, while only six Cox regression studies applied bootstrapping as validation procedure. As the choice of a reliable validation method strongly determines both performance and generalizability of models (25), this methodological discrepancy may have biased our findings. Validation issues were also present in studies employing ML for prognostic modelling. Fifty-three percent of these studies applied CV without nesting and repetitions, which is known to generate over-optimistic results due to its high variability and its information leakage between training and testing data during model optimisation (83) .
The extended use of this validation scheme may explain the higher sensitivity found in ML studies.
Second, several Cox regression studies included in this meta-analysis either didn't report probability thresholds or chose a priori 'optimal' thresholds from the data. configuration is learned by the model itself (84) .
It should be noted that some of the studies included in our meta-analytic contribution had very low sample size: Overall one study with N<20, 2 diagnostic and 21 prognostic models with less than 20, respectively, CHR individuals and CHR with poor outcome.
Findings from these studies might be consistent with literature demonstrating a publication bias towards increased accuracy with reduced sample size (85), possibly caused by overfitting. This indicates the need for future ML research to employ larger, preferably multi-site samples for both diagnostic and prognostic purposes. (85) .
Taken together, these issues may mirror the heterogeneity of methodological procedures within the field. Arguably, the application of ML techniques to diagnosis and prognosis in psychiatry is still relatively young (24), so conventions and standard operating procedures facilitating model comparability and replicability have not become generally accepted. Our findings highlight the urgency to develop such guidelines for the construction of prognostic and diagnostic models (86) . As indicated in Table 3, 
Type of data modality
Overall, most models were constructed using biological (44%) and clinical data (38%), with only ten prognostic models based on more than one data modality. Most diagnostic models used MRI data (83%), whereas prognostic models showed a higher variability.
Prognostic models of psychosis transition ranged from molecular, neuroanatomical, electrophysiological, neuropsychological and clinical data modalities, most of the latter trained on prodromal positive and negative symptoms, functioning, and familial risk associated with functional decline. We found no significant differences in predictive accuracy when comparing data modalities within and between algorithms.
This result may mirror a real lack of significant differences in biomarker type when either distinguishing the CHR state from the norm or predict outcome. However, as only four prognostic studies tested the relative and combined predictive ability of different data modalities on the same individuals (10, 30, 52, 56) , and as data modalities are, overall, under-or overrepresented, the currently available studies do not allow to draw this conclusion. Further research directly comparing performance across data modalities, followed by meta-analytic evaluation, is warranted.
Alternatively, our results may reflect the complexity of the multifaceted architecture of psychosis risk (87), which might be only partly captured by single data modalities. Indeed, a neuroanatomical biomarker might be informative for genetically or pathophysiologicaldriven mechanisms, given that genes' effect may be closer to brain than to behaviour (88); on the other hand, neurocognitive performance might explain more environmental-driven variance relating e.g. to socio-economic status (89) . Hence, a multimodal approach may be a viable way to reconcile and leverage information from single risk domains. Powerful new methodologies able to combine multiple sources of data, like, for instance, similarity network fusion (90), might serve the scope. Research showed that a combination of clinical variables and structural brain imaging data might represent a promising multimodal framework for psychosis prediction (10, 23, 31) . Along these lines, Schmidt et al. (2017)(29) devised a 3-stage sequential testing paradigm, which in theory reaches almost perfect positive predictive value when individuals are tested on one multimodal (i.e., clinical and EEG) and two biological data modalities (i.e., structural MRI and blood-based). However, these findings are simulated, haven't been confirmed in empirical studies yet, and did not follow a thorough meta-analytical approach like the one implemented here.
Alternatively, the similar performance of tested data modalities may have resulted from the variability induced by higher-order algorithm-data-validation interactions. To thoroughly compare models originating from different data spaces, methodological consensus guidelines are urgently needed in the precision psychiatry field. A strict cross-study standardization, both in terms of data definitions and algorithm implementations, may shed light on real phenotypic and neurobiological differences, thus lead to unique insights into the pathology of emerging psychosis. Notably, CHR populations differ not only in their clinical picture, but also along demographic and sociocultural dimensions (94) . For instance, American CHR individuals are usually younger (~16-18 years old) than their European counterparts (~22-24 years old). Interestingly, recent research has shown that neuroanatomical development and risk for developing psychosis are interconnected (95, 96) . This evidence might also reveal neurobiological processes leading to neurocognitive changes in the CHR state (97, 98) .
At-risk state/sample differences
Overall, our findings suggest that the gestalt of the CHR state may only be successfully modelled if multiple behavioural and neurobiological moderators are conjointly considered using standardised multivariate methods, thus fully embracing the complexity of this risk paradigm.
Limitations
Our meta-analysis was driven by the primary aim to evaluate the potential applicability of diagnostic and prognostic models in real-life clinical practice. Therefore, we focused only on the two currently prevailing methodological approaches(i.e., ML and Cox regression).
Importantly, we might have missed significant results by excluding other more traditional statistical methods, like logistic regression (15, 63) , which has been often implemented for prognostic purposes (15, 63) , eventually showing higher performance than ML (99) .
Nevertheless, ML approaches enable the investigation of the intrinsic complexity of specific data types (e.g., brain features) and are devised for better generalizability.
Another limitation might be the lack of investigation on symptomatology, treatment, substance use or additional comorbidities, which was due to missing or inconsistent information for several studies. Indeed, already in first-episode psychosis patients, antipsychotic treatment has shown to have neuroanatomical effects (100) and continuous cannabis use to lead to worse outcomes (101) . It is indeed plausible that the high variability of symptoms and clinical comorbidities in the CHR population (13) has further introduced spurious variance in our analyses.
Furthermore, the CHR paradigm has proven to have intrinsic limitations. On one hand, its predictive power might be partly driven by the so-called pre-test risk enrichment, i.e., the assessment of at-risk criteria in a specific constellation of help-seeking individuals (102, 103) . On the other hand, it may not capture the full extent of risk in the population, as a recent study pointed out by reporting that most of transitions occurred in patients with a psychiatric diagnosis, yet unclear or no CHR status (9) . As most prognostic models have been developed for the CHR state, their usefulness outside of this category should be intensively investigated.
Lastly, given the heterogeneity of our data and the publication bias detected, our meta-analysis is inherently limited to a description, not an ultimate decision, on which diagnostic and prognostic models are sufficiently reliable to be applied in clinical settings.
Conclusions
A comprehensive paradigm shift is required to enable the clinical application of diagnostic and prognostic models for the CHR state. First, the field requires study design harmonization, which demands reliable methodological approaches like cross-or external validation to ensure generalizability. An approach to enhance the studies' potential for (HARMONY) is a first step into the above direction. Consortium-wise coordinated work will also allow to perform strategic methodological testing, i.e., controlled comparison of algorithms, pre-processing and feature optimization pipelines, as well as multiple data modalities (for an overview of conceptual and methodological guidelines see Table 3 ).
Multimodal ML carries the challenging responsibility to better disentangle the complex architecture of psychosis risk within a clinical consensus environment. This should involve efforts in unifying the CHR definition, both theoretically and practically, and also embrace relevant non-transition outcomes to broaden the prognostic scope. Future studies are warranted to investigate whether harmonising procedures within precision psychiatry will lead to more reliable and reproducible translational research in the field.
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